Logo image of GRTS

GRITSTONE BIO INC (GRTS) Stock Fundamental Analysis

NASDAQ:GRTS - Nasdaq - US39868T1051 - Common Stock - Currency: USD

0.0322  -0.01 (-31.78%)

After market: 0.026 -0.01 (-19.25%)

Fundamental Rating

2

Overall GRTS gets a fundamental rating of 2 out of 10. We evaluated GRTS against 566 industry peers in the Biotechnology industry. GRTS may be in some trouble as it scores bad on both profitability and health. GRTS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRTS had negative earnings in the past year.
In the past year GRTS has reported a negative cash flow from operations.
GRTS had negative earnings in each of the past 5 years.
In the past 5 years GRTS always reported negative operating cash flow.
GRTS Yearly Net Income VS EBIT VS OCF VS FCFGRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of GRTS (-93.33%) is worse than 75.31% of its industry peers.
GRTS has a Return On Equity of -599.53%. This is amonst the worse of the industry: GRTS underperforms 80.64% of its industry peers.
Industry RankSector Rank
ROA -93.33%
ROE -599.53%
ROIC N/A
ROA(3y)-51.54%
ROA(5y)-50.67%
ROE(3y)-123.97%
ROE(5y)-101.08%
ROIC(3y)N/A
ROIC(5y)N/A
GRTS Yearly ROA, ROE, ROICGRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRTS Yearly Profit, Operating, Gross MarginsGRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

GRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GRTS has more shares outstanding
The number of shares outstanding for GRTS has been increased compared to 5 years ago.
The debt/assets ratio for GRTS is higher compared to a year ago.
GRTS Yearly Shares OutstandingGRTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
GRTS Yearly Total Debt VS Total AssetsGRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

GRTS has an Altman-Z score of -9.83. This is a bad value and indicates that GRTS is not financially healthy and even has some risk of bankruptcy.
GRTS has a Altman-Z score of -9.83. This is in the lower half of the industry: GRTS underperforms 75.67% of its industry peers.
A Debt/Equity ratio of 1.83 is on the high side and indicates that GRTS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.83, GRTS is doing worse than 81.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACC7.5%
GRTS Yearly LT Debt VS Equity VS FCFGRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

GRTS has a Current Ratio of 2.54. This indicates that GRTS is financially healthy and has no problem in meeting its short term obligations.
GRTS has a Current ratio of 2.54. This is in the lower half of the industry: GRTS underperforms 71.58% of its industry peers.
A Quick Ratio of 2.54 indicates that GRTS has no problem at all paying its short term obligations.
GRTS's Quick ratio of 2.54 is on the low side compared to the rest of the industry. GRTS is outperformed by 70.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.54
GRTS Yearly Current Assets VS Current LiabilitesGRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.49% over the past year.
GRTS shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.14%.
Measured over the past years, GRTS shows a very strong growth in Revenue. The Revenue has been growing by 68.87% on average per year.
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
Revenue 1Y (TTM)25.14%
Revenue growth 3Y59.34%
Revenue growth 5Y68.87%
Sales Q2Q%-52.89%

3.2 Future

The Earnings Per Share is expected to grow by 16.58% on average over the next years. This is quite good.
GRTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 74.91% yearly.
EPS Next Y19.29%
EPS Next 2Y8.07%
EPS Next 3Y1.48%
EPS Next 5Y16.58%
Revenue Next Year-74.34%
Revenue Next 2Y-41.42%
Revenue Next 3Y2.57%
Revenue Next 5Y74.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
GRTS Yearly Revenue VS EstimatesGRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 200M 400M 600M 800M
GRTS Yearly EPS VS EstimatesGRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRTS Price Earnings VS Forward Price EarningsGRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRTS Per share dataGRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.07%
EPS Next 3Y1.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRITSTONE BIO INC

NASDAQ:GRTS (10/21/2024, 8:17:44 PM)

After market: 0.026 -0.01 (-19.25%)

0.0322

-0.01 (-31.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/amc
Earnings (Next)11-07 2024-11-07/amc
Inst Owners30.17%
Inst Owner Change0%
Ins Owners7.44%
Ins Owner Change-5.31%
Market Cap3.80M
Analysts43.33
Price Target0.77 (2291.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.93%
Min EPS beat(2)-4.7%
Max EPS beat(2)44.55%
EPS beat(4)3
Avg EPS beat(4)16.23%
Min EPS beat(4)-4.7%
Max EPS beat(4)44.55%
EPS beat(8)7
Avg EPS beat(8)14.69%
EPS beat(12)11
Avg EPS beat(12)14.99%
EPS beat(16)13
Avg EPS beat(16)20.82%
Revenue beat(2)1
Avg Revenue beat(2)10.25%
Min Revenue beat(2)-34.21%
Max Revenue beat(2)54.71%
Revenue beat(4)2
Avg Revenue beat(4)25.15%
Min Revenue beat(4)-34.21%
Max Revenue beat(4)99.1%
Revenue beat(8)3
Avg Revenue beat(8)9.85%
Revenue beat(12)7
Avg Revenue beat(12)19.44%
Revenue beat(16)10
Avg Revenue beat(16)29.53%
PT rev (1m)-81.25%
PT rev (3m)-80.43%
EPS NQ rev (1m)-7.41%
EPS NQ rev (3m)20.85%
EPS NY rev (1m)-5.33%
EPS NY rev (3m)11.86%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-47.38%
Revenue NY rev (3m)-81.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.12
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.33%
ROE -599.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.54%
ROA(5y)-50.67%
ROE(3y)-123.97%
ROE(5y)-101.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.16%
Cap/Sales 9.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.54
Altman-Z -9.83
F-Score3
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)78.57%
Cap/Depr(5y)125.83%
Cap/Sales(3y)22.91%
Cap/Sales(5y)105.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
EPS Next Y19.29%
EPS Next 2Y8.07%
EPS Next 3Y1.48%
EPS Next 5Y16.58%
Revenue 1Y (TTM)25.14%
Revenue growth 3Y59.34%
Revenue growth 5Y68.87%
Sales Q2Q%-52.89%
Revenue Next Year-74.34%
Revenue Next 2Y-41.42%
Revenue Next 3Y2.57%
Revenue Next 5Y74.91%
EBIT growth 1Y-3.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.16%
EBIT Next 3Y-2.82%
EBIT Next 5YN/A
FCF growth 1Y-7.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.73%
OCF growth 3YN/A
OCF growth 5YN/A